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Pharmaceuticals are a group of intrinsically 
bioactive chemicals used in humans and ani-
mals for disease treatment and prevention and 
growth promotion, among other purposes. 
These chemicals have also been regarded as 
environ mental contaminants in recent decades 
because of their potential toxicity to nontarget 
organisms and their ubiquitous occurrence in 
the environment due to extensive and continu-
ous release from sources including municipal, 
hospital, agricultural, and industrial effluents 
(Segura et al. 2009).
Potable water sources are contaminated 
by human and veterinary pharma ceuticals 
(Huerta-Fontela et al. 2008, 2011; Watkinson 
et al. 2009). Incomplete removal by conven-
tional technologies (e.g., flocculation, sedimen-
tation, and chlorination) in drinking- water 
treatment plants (DWTPs) has been observed, 
and consequently, pharma ceuticals have 
been detected in tap water in several devel-
oped countries at levels of usually < 100 ng/L 
(Segura et al. 2009). Although pharmaceutical 
levels in drinking water are currently unregu-
lated, efforts have been made to include them 
in environmental monitoring programs. The 
U.S. Environmental Protection Agency (EPA) 
recently added 10 active ingredients to the 
Third Contaminant Candidate List (CCL 3) 
(U.S. EPA 2009a) and proposed the inclusion 
of seven hormones in the third Unregulated 
Contaminant Monitoring Regulation (U.S. 
EPA 2011) as reference for future amend-
ment of drinking-water regulations. The New 
York Environmental Protection Department 
(NYCDEP) also conducted a 1-year pilot 
scheme for pro active monitoring of pharma-
ceuticals in source water (NYCDEP 2010). 
Provisional safety levels for pharma ceuticals 
in drinking water, known as drinking-water 
equivalent levels (DWELs), have also been 
derived by a few research groups based on 
available chronic mammalian toxicity data, 
minimum inhibitory concentrations, or the 
lowest therapeutic doses (Bruce et al. 2010; 
Schwab et al. 2005). Individual pharma-
ceuticals are expected to pose negligible human 
health risks in tap water based on known 
levels in studied regions [World Health 
Organization (WHO) 2012].
Data on pharmaceutical concentrations in 
drinking water are available for some devel-
oped countries, but relevant information in 
developing countries is scarce (Segura et al. 
2009). In China, human and veterinary 
pharma ceuticals have frequently been detected 
in wastewater and surface waters at concentra-
tions of generally < 1 µg/L; levels of certain 
compounds, such as erythromycin- H2O, sali-
cylic acid, and cefalexin, have been reported to 
be at the high end of the values reported glob-
ally (Jiang et al. 2011; Leung et al. 2012; Wei 
et al. 2011), and illegal use of prohibited vet-
erinary drugs has been detected in slaughter-
house wastewater (Shao et al. 2009). However, 
the human health risks of pharma ceuticals 
in drinking water have not been evaluated to 
date. This information is needed for evaluating 
risk management and regulation with regard to 
pharmaceutical contamination in China.
In recognition of these concerns, the 
objectives of this study were a) to investi-
gate the occurrence of 32 pharmaceutically 
active ingredients in drinking water in 13 cit-
ies in China; b) to assess and prioritize the 
potential risks of pharmaceutical exposure in 
the Chinese population via drinking water 
based on available or newly derived DWELs, 
with emphasis on exposure at different life 
stages; and c) to identify and suggest possible 
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Background: Pharmaceuticals are known to contaminate tap water worldwide, but the relevant 
human health risks have not been assessed in China.
oBjectives: We monitored 32 pharma ceuticals in Chinese tap water and evaluated the life-long 
human health risks of exposure in order to provide information for future prioritization and 
risk management.
Methods: We analyzed samples (n = 113) from 13 cities and compared detected concentrations 
with existing or newly-derived safety levels for assessing risk quotients (RQs) at different life stages, 
excluding the prenatal stage.
results: We detected 17 pharma ceuticals in 89% of samples, with most detectable concentrations 
(92%) at < 50 ng/L. Caffeine (median–maximum, nanograms per liter: 24.4–564), metronidazole 
(1.8–19.3), salicylic acid (16.6–41.2), clofibric acid (1.2–3.3), carbamazepine (1.3–6.7), and dime-
tridazole (6.9–14.7) were found in ≥ 20% of samples. Cities within the Yangtze River region and 
Guangzhou were regarded as contamination hot spots because of elevated levels and frequent positive 
detections. Of the 17 pharma ceuticals detected, 13 showed very low risk levels, but 4 (i.e., dimetrid-
azole, thiamphenicol, sulfamethazine, and clarithromycin) were found to have at least one life-stage 
RQ ≥ 0.01, especially for the infant and child life stages, and should be considered of high priority 
for management. We propose an indicator-based monitoring framework for providing information 
for source identification, water treatment effectiveness, and water safety management in China.
conclusion: Chinese tap water is an additional route of human exposure to pharma ceuticals, par-
ticularly for dimetridazole, although the risk to human health is low based on current toxicity data. 
Pharmaceutical detection and application of the proposed monitoring framework can be used for 
water source protection and risk management in China and elsewhere.
key words: China, indicator, life stage, pharma ceuticals, risk assessment, tap water.
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molecu lar indicators for comprehensive moni-
toring and for risk management of pharma-
ceuticals in China and elsewhere.
Methods
Selected pharma ceuticals, sampling, and 
analysis. We analyzed a total of 32 pharma-
ceuticals of 16 different therapeutic classes [see 
Supplemental Material, p. 2, Table S1 (http://
dx.doi.org/10.1289/ehp.1206244)]. Because 
production amounts and usage patterns of 
pharma ceuticals in China are currently unclear 
and because there is no guidance provided 
by Chinese regulatory agencies for analyte 
selection, the target compounds in the pres-
ent study were selected based on a) reported 
detections in waste water and surface water in 
China, Vietnam, and other developed coun-
tries; b) representative coverage of different 
pharmaceutical classes (e.g., human and vet-
erinary pharma ceuticals); c) potential toxic-
ity (e.g., evidence of carcinogenicity); and 
d) existing Chinese regulations (e.g.,  prohibited 
 pharma ceuticals such as nitroimidazoles).
We collected 113 household tap-water 
samples from 13 major Chinese cities (Beijing, 
Yancheng, Nanjing, Hangzhou, Shanghai, 
Wuhan, Changsha, Xiamen, Guangzhou, 
Zhuhai, Macau, Shenzhen, and Hong Kong) 
in the dry season (October 2010–February 
2011, n = 67); 9 cities (excluding Beijing, 
Yancheng, Xiamen, Wuhan) were sampled 
again in the wet season (June 2011–July 
2011, n = 46) [see Supplemental Material, 
p. 2, Table S2 and Figure S1 (http://dx.doi.
org/10.1289/ehp.1206244)].
We collected 5 or 6 1-L replicates from 
private residences in each city in different 
urban and residential districts, stored them in 
polypropylene bottles covered with aluminum 
foil, fortified them with ascorbic acid for 
quenching chlorine residues, and extracted 
them within 48 hr of collection. The targeted 
pharma ceuticals were extracted with solid phase 
extraction methodology previously applied for 
sewage (Leung et al. 2012) with modifications 
for broadening the number of analytes, and the 
pharma ceuticals were quantified using high-
performance liquid chromatography–tandem 
mass spectrometry (HPLC-MS/MS) [see 
Supplemental Material, pp. 3–4 (http://dx.doi.
org/10.1289/ehp.1206244)].
Derivation of DWELs and risk assess-
ment. For detected compounds, the accept-
able daily intake (ADI) or risk-specific dose 
(RSD) for noncarcinogenic and carcinogenic 
effects, respectively, were either adopted from 
provisional values established in the literature 
or derived using toxicological, microbiologi-
cal, or therapeutic approaches applied previ-
ously [Bruce et al. 2010; Schriks et al. 2010; 
Schwab et al. 2005; see also Supplemental 
Material, pp. 4–6 (http://dx.doi.org/10.1289/
ehp.1206244)].
The most restrictive ADI or RSD for each 
pharmaceutical was converted to a DWEL 
based on daily ingestion rate of drinking water 
and body weight. To reduce the uncertain-
ties in exposure variation among life stages, 
we used age-specific 95th percentile values of 
daily water ingestion per body weight for 12 
age intervals ranging from birth to 70 years 
according to the U.S. EPA Exposure Factor 
Handbook [U.S. EPA 2009b; age-specific val-
ues are summarized in Supplemental Material, 
Table S3 (http://dx.doi.org/10.1289/
ehp.1206244)] for estimating age-dependent 
DWELs using Equation 1:
DWEL (ng/L) = [(ADI or RSD)  
 × RSCDW × BW × 1,000] 
 ÷ IngRDW, [1]
where RSCDW represents the relative source 
contribution of acceptable dose from drink-
ing water, assumed to be 100% for screening 
purposes because unintended ingestion of 
pharma ceuticals occurs mainly via drinking 
water (Cunningham et al. 2009) except for 
caffeine, for which 10% was used as a default 
factor for general contaminants (WHO 
2008); 1,000 represents the unit conver-
sion from micrograms to nanograms; and 
IngRDW represents the daily ingestion rate 
of water.
We calculated an age-dependent risk 
 quotient (RQ) for each pharmaceutical by 
dividing the highest concentration in tap water 
by its age-dependent DWEL. The individual 
RQs of the 12 age intervals were integrated into 
a lifetime RQ profile. Pharmaceuticals with 
RQ ≥ 1 could potentially affect human health.
Results and Discussion
Occurrence and spatiotemporal distribution. 
Seventeen pharma ceuticals—including 11 
human and veterinary antibiotics (macrolides, 
sulfonamides, thiamphenicol, nitroimidazoles, 
trimethoprim), 2 nonsteroidal antiinflam-
matory drugs (salicylic acid, diclofenac), a 
β-blocker (metoprolol), a lipid regulator (clofi-
bric acid), a psychoactive stimulant (caffeine), 
and an anticonvulsant (carbamazepine)—were 
quantified (Figure 1). One or more com-
pounds were detected in 89% of samples (cal-
culated by dividing the number of samples 
containing ≥ 1 compound by the total sample 
number), with 92% of detectable concentra-
tions < 50 ng/L (calculated by dividing the 
number of positive detections of all analytes 
with concentrations of < 50 ng/L by the total 
number of positive detections), except for caf-
feine, sulfamethazine, and thiamphenicol.
Spatiotemporal distributions of nine com-
pounds that were either detected in ≥ 10% 
of samples or whose maximum levels were 
> 50 ng/L are shown in Figure 2. Tap water 
collected from cities in the Yangtze River 
region (Nanjing and Hangzhou), together 
with Guangzhou and Wuhan, was found 
to have a detection index ≥ 3 {calculated by 
dividing the total number of positive detec-
tions by the number of samples in each city 
[see Supplemental Material, Table S4 (http://
dx.doi.org/10.1289/ehp.1206244)] and con-
centrations}, indicating that source waters were 
more affected by municipal and/or agricultural 
wastewater. These cities should be regarded 
as contamination hot spots of special con-
cern. The maximal levels of all detected com-
pounds were found during the dry season, and 
Figure 1. Concentrations of 17 detected pharma ceuticals in Chinese tap water. The percentage of samples 
with positive detections are shown in parentheses for each compound; sulfathiazole and metoprolol were 
only detected in a single sample each and their respective concentrations were regarded as maximum 
levels and shown as horizontal bars.
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six pharma ceuticals—roxithromycin, tylosin, 
sulfathiazole, trimethoprim, metoprolol, and 
diclofenac—were exclusively detected during 
this period. Slower river flow and lower bio-
degradation and photodegradation rates are 
the likely reasons for elevated levels in the dry 
season as reported for source river water in 
China (Jiang et al. 2011), the United States 
(Loraine and Pettigrove 2006), and Finland 
(Vieno et al. 2007).
Human pharma ceuticals. Caffeine, 
which occurs both naturally and as a com-
mon food additive, was the most prevalent 
compound detected, occurring in ~ 88% 
of samples at a median concentration of 
24.4 ng/L (Figure 1), but exceeding 400 ng/L 
(maximum, 564 ng/L) in a few samples from 
Hangzhou (Figure 2). In a global compari-
son, caffeine levels in Chinese tap water were 
highest among tap-water and source-water 
samples collected from developed countries, 
including the United States, Spain, and 
France (Figure 3). Caffeine has been iden-
tified as a marker for anthropogenic con-
tamination in both munici pal sewage and 
surface waters (Daneshvar et al. 2012). Its 
widespread occurrence in all sampled cities 
except Beijing revealed differing impacts of 
municipal sewage on source water as well as 
of the ineffective treatment methods currently 
in use in DWTPs throughout the studied 
regions (Figure 2). The nondetectable levels 
of caffeine and most of the target analytes in 
Beijing could be attributed to the better 
quality of source water {67% is groundwa-
ter [National Bureau of Statistics of China 
(NBSC) 2009]} and also to popular utilization 
[49% (Beijing Waterworks Group 2008)] of 
advanced technologies including ozonation 
and activated carbon adsorption. It should 
be noted that these water- treatment methods 
are still rare in most Chinese DWTPs [see 
Supplemental Material, Table S2 (http://
dx.doi.org/10.1289/ehp.1206244)].
Insufficient sewage treatment is a domi-
nant factor explaining contamination of 
Chinese water sources. Municipal sewage is the 
primary source of caffeine and other human 
pharma ceuticals to surface waters, but only 
an average of 65% of sewage is conveyed to 
sewage treatment plants (STPs) before dis-
charge (NBSC 2009). Indeed, up to 40% 
of major streams and almost all freshwater 
lakes have been severely impacted and clas-
sified as Type IV or below, “unsuitable for 
drinking purposes,” according to a national 
report (NBSC 2009). The DWTP is the last 
safeguard for preventing human exposure 
to chemicals in source water, but DWTPs 
are not designed specifically to attenuate 
pharma ceuticals. Among the sampled cit-
ies, 80% of tap-water supplies are treated by 
coagulation– sedimentation– chlorination, of 
which only chlorination reacts selectively with 
pharma ceuticals possessing electron-rich bonds 
such as sulfonamides and phenolic pharma-
ceuticals but not with caffeine and carbamaze-
pine (Huerta-Fontela et al. 2008; Snyder et al. 
2007). Ineffective attenuation of caffeine or 
other chemicals with similar properties during 
conventional treatment could account for their 
ubiquity in chlorinated tap water.
Unlike caffeine, other human pharma-
ceuticals were detected much less frequently in 
tap water. Salicylic acid (median–maximum, 
16.6–41.2 ng/L), clofibric acid (1.2–3.3 ng/L), 
and carbamazepine (1.3–6.7 ng/L) were 
found in 23–33% of samples, followed by 
three macrolide antibiotics (clarithro mycin, 
6.7–11.9 ng/L; roxithromycin, 2.8–15.1 ng/L; 
azithromycin, 7.1–11.7 ng/L) and sulfa-
methoxazole (8.0–21.3 ng/L) in 7.1–8.8% 
of samples [Figure 1; see also Supplemental 
Material, Table S4 (http://dx.doi.org/10.1289/
ehp.1206244)]. As shown in Figure 3, levels 
of carbamazepine, clofibric acid, and sulfa-
methoxazole were either comparable to or 
at the low end of detected values in Europe 
and North America. Gemfibrozil was not 
detected in this study, but it was present in 
nearly half of the treated water samples col-
lected in the United States (7 of 18 samples; 
median–maximum, 0.48–2.1 ng/L; Benotti 
et al. 2009). This general situation was in line 
with results for Chinese sewage and also in 
surface water in Vietnam where levels of many 
Figure 2. Spatiotemporal distribution of nine pharma ceuticals in Chinese tap water. Abbreviations: D, dry season; W, wet season.
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human pharma ceuticals were also lower than 
studies in developed countries (Managaki 
et al. 2007; Sui et al. 2010), possibly because 
of poorer socio e conomic status and limited 
access to some pharma ceuticals and thus less 
consumption per capita in China and other 
low- to middle-income countries (Chen and 
Schweitzer 2008; WHO 2011). However, 
given the rapid socioe conomic development 
rate of China, it is reasonable to foresee that 
pharmaceutical usage per capita may advance 
to levels comparable to those in developed 
countries. Frequent detections of some human 
pharma ceuticals in the current investigation 
should thus be regarded as early warning sig-
nals about the current sewerage systems, STP 
and DWTP treatment capabilities, and water 
source protection in China.
Veterinary pharma ceuticals. Six veteri-
nary pharma ceuticals—dimetridazole, metro-
nidazole, thiamphenicol, sulfamethazine, 
sulfathiazole, and tylosin—were found at 
median concentrations of 1.8–17.8 ng/L and 
maximum levels of 7.0–104 ng/L [Figure 1; 
see also Supplemental Material, Table S4 
(http://dx.doi.org/10.1289/ehp.1206244)].
The two most prevalent veterinary pharma-
ceuticals—dimetridazole (median–maximum, 
6.9–14.7 ng/L; detection frequency, 20%) and 
metronidazole (1.8–19.3 ng/L; 40%)—were 
localized to Guangzhou, Wuhan, Changsha, 
and the Yangtze River region, particularly in 
Nanjing in Jiangsu Province, where veterinary 
pharma ceuticals have been reported to be 
widespread in surrounding surface waters (Wei 
et al. 2011). Metronidazole and dimetridazole 
have not been measured in tap water elsewhere 
in the world as far as we are aware. The lack 
of global information may be attributed 
to their restricted use in many developed 
countries because of potential carcinogenicity 
in mammals [Australian Pesticides and 
Veterinary Medicines Authority (APVMA) 
2007; European Agency for the Evaluation 
of Medicinal Products 1997]. The United 
States, Canada, and Australia confine the 
use of dimetridazole to non–food-producing 
animals, and the European Union (EU) has 
banned veterinary administration of both 
compounds (APVMA 2007; EU 2010). In 
contrast, use of these two nitroimidazoles is 
authorized for therapy in food-producing 
animals in China but detectable residue levels 
in food commodities are prohibited (Ministry 
of Agriculture of The People’s Republic 
of China 2002). Our findings show that 
tap water would be an additional route of 
human exposure in China to these prohibited 
veterinary drugs other than via food ingestion, 
potentially increasing human health risk.
Sulfamethazine and thiamphenicol were 
only found in 5.3% and 12% of samples, 
but their respective maximum levels reached 
89.6 ng/L in Shanghai and 104.3 ng/L in 
Hangzhou [see Supplemental Material, 
Table S4 (http://dx.doi.org/10.1289/
ehp.1206244)]. Sulfamethazine was not 
detected in raw water in a 1-year monitor-
ing study in the United States and the maxi-
mum concentration in raw water (40 ng/L) 
in another U.S. study was only half of that 
detected in the present study (NYCDEP 
2010; Stackelberg et al. 2007) (Figure 3). 
Shanghai’s water source, the Huangpu River, 
has been deteriorated by STP and animal hus-
bandry effluents, and it has been reported to 
contain sulfamethazine at a maximum level 
of 623 ng/L (Jiang et al. 2011). Substantially 
higher detection frequencies and environ-
mental levels of sulfamethazine were found 
in Jiangsu Province in China [detected in 
88% of 18 samples, median–maximum, 100–
4660 ng/L (Wei et al. 2011)] and in Hanoi, 
Vietnam [100% of 20 samples, 81–328 ng/L 
(Managaki et al. 2007)], compared with a 
national reconnaissance of pharma ceuticals 
in streams across the United States, which 
reported a few detections of sulfamethazine at 
low levels [4.8% of 104 samples, 20–120 ng/L 
(Kolpin et al. 2002)]. Veterinary pharmaceuti-
cal contamination in drinking-water sources 
could be a characteristic problem in China 
and/or other developing countries because of 
the combination of extensive agribusiness and 
resultant large-scale release of veterinary medi-
cines from animal breeding farms with inad-
equate waste treatments as well as agricultural 
surface runoff (Jiang et al. 2011; Managaki 
et al. 2007; Tong et al., 2009; Wei et al. 
2011). Moreover, poor source-water quality 
could affect treatment efficiencies in DWTPs. 
Given the substantial reactivity of the aniline 
moiety in sulfonamides during chlorination, 
their presence in tap water was unexpected. 
High levels of coexisting sewage-derived 
chemicals such as ammonia may compete for 
free chlorine and thus interfere with expected 
treatment efficiency (Dodd and Huang 2004).
Human health risk assessment. Previous 
risk assessments of pharma ceuticals in drink-
ing water have employed different approaches, 
but life-stage–specific exposure was not con-
sidered, other than applying default values of 
body weight and drinking-water rate for adults 
(70 kg; 2 L/day) and for children (10 or 14 
kg; 1 L/day) (U.S. EPA 2008). We attempted 
to reduce uncertainty in the exposure assess-
ment by integrating different age-specific expo-
sure factors for evaluating life-stage risks. The 
current approach is more conservative and 
can be modified further by incorporation of 
age-specific adjustment factors if a pharma-
ceutical is known to be particularly toxic to 
a certain life stage according to variability in 
toxicokinetics and toxicodynamics (Daston 
et al. 2004; Ginsberg et al. 2004). However, 
Figure 3. Worldwide comparison of detected pharma ceuticals in Chinese tap water. The lower and upper 
bounds of each box indicate median and maximum values, respectively; ND raw/finished, pharmaceutical 
not detected in raw/finished water. 
Data from aStackelberg et al. (2007); bNYCDEP (2010); cBenotti et al. (2009); dBoyd et al. (2003); eLoraine and Pettigrove 
(2006); fKim et al. (2007); gWatkinson et al. (2009); hVieno et al. (2007); iHeberer (2002); jTogola and Budzinski (2008); 
kZuccato et al. (2000); lHuerta-Fontela et al. (2008).
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one limitation of the present study is that there 
is no detailed information about drinking-
water consumption rates and body weights of 
the Chinese population, and thus data from 
the U.S. EPA Exposure Factors Handbook 
(U.S. EPA 2009b) was used as the basis for risk 
assessment. Nevertheless, the current assess-
ment can be considered a proactive human 
health risk assessment of pharma ceuticals in 
Chinese tap water and a reference for future 
risk  management in China.
The most restrictive ADIs or RSDs for 
the detected pharma ceuticals ranged from 
0.006 to 150 µg/kg/day for different health 
end points [see Supplemental Material, 
Table S3 (http://dx.doi.org/10.1289/
ehp.1206244)]. Pharmaceuticals were cate-
gorized into three groups: a) Group 1, at least 
one life-stage RQ ≥ 0.01; b) Group 2, 0.01 
> all life-stage RQs ≥ 0.0001; c) Group 3, 
most life-stage RQs < 0.0001, and lifetime 
RQ profiles from birth to 70 years of age were 
plotted (Figure 4). Generally, life-stage RQs 
of the 17 assessed pharma ceuticals for the 12 
age intervals ranged from 0.5 to < 0.0001, 
of which 13 were either in Group 2 or 3, 
and thus were at least 2 orders of magnitude 
lower than their DWELs (see Supplemental 
Material, Table S3). Among the assessed life 
stages, RQs in infants (birth to < 12 months) 
and children (age 1 to < 11 years) were at least 
1.2–5.8 times greater than the approximately 
constant RQs throughout adolescence and 
adulthood (Figure 4). Greater drinking-water 
ingestion on a body-weight basis in these early 
life stages could account for higher exposure 
levels and thus higher risks than in adults.
Three veterinary medicines (dimetrid-
azole, thiamphenicol, and sulfamethazine) 
and a human pharmaceutical (clarithromycin) 
were classified into Group 1. The DWELs 
of clarithromycin, thiamphenicol, and 
sulfamethazine were derived based on inhibi-
tion of intestinal microbes, hemotoxic 
effects, and potential incidence of thyroid 
gland follicul ar adenoma, respectively [see 
Supplemental Material, Table S3 (http://
dx.doi.org/10.1289/ehp.1206244)]; these 
Group 1 compounds exceeded their respec-
tive criterion only for a relatively short period 
(< 1 year) after birth. As the relevance of the 
toxicological end points used for DWEL 
derivation to infant health is unclear, fur-
ther investigation of the effects of early-
life exposure to these three compounds is 
needed to determine their potential risks. It 
should be noted that dimetridazole, a poten-
tial carcinogen and a prohibited residue in 
food commodities in China, presented the 
highest risks in tap water, although all life-
stage RQs (0.08–0.53) were < 1. The maxi-
mum environmental concentration of 
dimetridazole (14.7 ng/L) was on the same 
order of magnitude as its age-dependent 
DWELs (27.8–184 ng/L). The current screen-
ing assessment considered the RSC of ADI 
from tap-water ingestion to be 100%, but the 
possibility of 20–80% contribution from tap 
water was also estimated (Bruce et al. 2010). 
In the conservative case of RSC equal to 20%, 
life-stage RQs of dimetridazole (0.40–2.65) 
increase by five times and it is potentially risky 
(RQ > 1) to infants for their first year of life. 
The end point used for DWEL derivation was 
the incidence of benign mammary tumors in 
rats under chronic exposure [no slope factor 
was determined; no observable adverse effect 
level = 4,200 µg/kg/day, average value of both 
sexes, was thus regarded as the maximum tol-
erated dose applied (Lowe et al. 1976; see also 
Supplemental Material, pp. 4–6, Equation 
S3)]. Childhood exposure to potential 
carcino gens is of particular concern because 
of children’s immature defense systems and 
rapid growth rate (U.S. EPA 2005). In addi-
tion, children also have a longer time frame 
for developing chronic diseases such as cancer 
initiated in any critical window early in their 
lives (Landrigan et al. 2004). As a result, risk 
management of this compound should be of 
first priority. Nevertheless, our results affirm 
those reported in the literature and inter-
nationally that appreciable risks of most indi-
vidual pharma ceuticals in tap water to human 
health are unlikely based on available toxicity 
data (Schwab et al. 2005; WHO 2012).
Although all of the detected pharma-
ceuticals posed low risk when considered 
individually, we also considered potential 
uncertainties in the analysis. One critical issue 
identified in a recent summit was that mixture 
toxicities and possible inter actions of these 
biologically active xeno biotics are not yet well 
understood, in particular chronic exposure to 
trace amounts of pharmaceutical mixtures and 
their corresponding metabolites (Rodriguez-
Mozaz and Weinberg 2010). Moreover, given 
that unique prenatal and early-life susceptibil-
ity to pharma ceuticals during critical windows 
of development may result in unanticipated 
adverse effects, there is also a need to evalu-
ate exposures to pharma ceuticals in tap water 
in utero and through breastfeeding in future 
life-stage assessments (Landrigan et al. 2004).
Risk management. China is currently lack-
ing a regulatory framework for preventing and 
mitigating the occurrence of human and veter-
inary pharma ceuticals in tap water. The water 
safety plan approach suggested by the WHO 
(2009) includes 11 modules and can be used 
as a backbone for targeting these emerging 
contaminants. Of the modules suggested by 
the WHO, we have focused on the following 
elements or stages: 
•	Hazards/targets identification and desktop-
based prioritization
Figure 4. Human health life-stage RQ profile of detected pharma ceuticals in Chinese tap water. (A) Pharmaceuticals with at least one life-stage RQ ≥ 0.01. 
(B) Pharmaceuticals with all life-stage RQs between 0.0001 and 0.01. (C) Pharmaceuticals with most life-stage RQs < 0.0001.
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•	Screening, risk assessment, and risk-based 
prioritization
•	Comprehensive monitoring program
•	Planning and implementation of mitigation 
measures and follow-up reassessment. 
The WHO approach is not specific to any 
group of contaminants or water qual-
ity parameters. Here, we have applied this 
general approach to establish a monitoring 
and risk assessment framework for pharma-
ceuticals in tap water (Figure 5). In the case 
of countries where usage information is lack-
ing, a semiquantitative estimation based on 
surveys of hospitals and practitioners could be 
an alternative information source in stage 1, 
or large-scale screening could be implemented 
in stage 2 if pharmaceutical contamination in 
raw and tap water is reasonably anticipated 
based on existing evidence. In this study, we 
applied the latter approach and identified loca-
tions and contaminants of concern in Chinese 
tap water for management prioritization.
Stages 3 and 4 of our framework involve 
intensive time, cost, and human resources, 
and the need for these efforts should be 
considered thoughtfully according to risk 
levels. Given the low risks currently posed 
by most of the measured pharma ceuticals 
in Chinese tap water, a routine national 
monitoring program and installation of 
specialized treatment infrastructure are not 
immediately warranted. However, regions 
with elevated levels (e.g., cities within the 
Yangtze River region) or frequent detection 
of potentially risky compounds (e.g., 
dimetridazole) require the application of a 
pro active monitoring framework based on a 
suite of indicator compounds with scenario-
based interpretations and recom mendations 
(Figure 5). In the present study, an indicator 
is regarded as a qualitative measure to reflect 
contami na tion by micro pollutants with simi-
lar sources and behaviors under different 
treatments and is also used to evaluate the 
efficacy of DWTP treatment (Dickenson 
et al. 2009). Indicators for micro pollutants 
described in the literature focused exclusively 
on municipal wastewater-derived compounds 
(e.g., caffeine, carbamazepine) (Gasser 
et al. 2010), but the frequent detection 
of both municipal and animal wastewater- 
derived pharma ceuticals suggests that 
corresponding indicators for both origins are 
particularly necessary in China and perhaps 
other developing countries. Therefore, we 
selected six indicators according to a) origin 
specificity, in which the indicator exclusively 
originates from either municipal or veterinary 
wastewater; b) behavior in DWTPs, in which 
the treatability of pharma ceuticals is classified 
based on chlorination, the most popular 
treatment method in China, but indicators for 
other advanced treatments (e.g., ozonation) 
could be further developed (Dickenson et al. 
2009); c) representativeness, in which the 
indicator should be commonly detected and 
at relatively higher concentrations. All of the 
selected indicators are cate gorized into four 
groups based on origin and removal efficiency 
by chlorination in DWTP (Figure 5):
•	Group A (municipal, effective): sulfa-
methoxazole
•	Group B (veterinary, effective): sulfa-
methazine
•	Group C (municipal, ineffective): caffeine 
and carbamazepine
•	Group D (veterinary, ineffective): dimetrid-
azole and metronidazole). 
Because the indicator in groups A and B is 
susceptible to chlorination, its presence in tap 
water may qualitatively indicate ineffective 
Figure 5. Risk management and indicator-based monitoring framework for pharma ceuticals in Chinese tap water.
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chlorination treatment and/or poor quality 
of raw water from which the indicator is not 
completely removed even under normal oper-
ating conditions; immediate verification of 
the operating conditions in the DWTP would 
therefore be suggested. Indicators in groups 
C and D directly reflect the water quality of 
raw water, and their presence may denote 
that water sources are negatively impacted. 
Upgrading current treatment technologies 
is a possible mitigation measure, but con-
trolling pharmaceutical inputs at contami-
nation sources is also highly recommended. 
Origins of impacts could be traced back and 
then further mitigated in terms of short-term 
measures (e.g., changes of effluent discharge 
points, relocations of nearby point sources, 
strengthening enforcement of potable water 
source protection) and also long-term regula-
tions (e.g., drug take-back programs, changes 
in pharmaceutical disposal practices, raising 
public awareness by education) (WHO 2012).
This indicator-based framework provides 
a) cost- and time-effective monitoring instead 
of requiring quantification of a broad range of 
pharmaceutical compounds; b) clues for trac-
ing and identifying potential contamination 
sources in raw water; c) insights into moni-
toring treatment effectiveness; and d) a ref-
erence for assisting regulatory authorities in 
decision making related to risk minimization 
and public health protection policies. This 
framework has been developed for Chinese 
tap water according to the results of the pres-
ent study, but it can be more widely applied. 
Selection of indicators will likely vary among 
countries based on patterns of pharma ceutical 
usage, DWTP treatment levels, and analytical 
capability; a relatively large-scale initial sur-
vey of pharmaceutical levels and patterns is 
therefore still needed for indicator identifi-
cation. Further development of the current 
indicator-based framework (e.g., broadening 
the number of suitable indicators to reflect 
other DWTP treatment types and effects of 
in-stream transportation) should be carried 
out for more a comprehensive and informative 
assessment of pharmaceutical risk in tap water.
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